Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04643418Phase 1Recruiting

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Role: lead

NCT06540443Phase 1Recruiting

Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas

Role: lead

NCT03485053Phase 2Terminated

A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia

Role: lead

NCT03407495Phase 2Completed

The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma

Role: lead

NCT03399214Phase 1Completed

Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects

Role: lead

NCT02744248Phase 1Completed

Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects

Role: lead

All 6 trials loaded